BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
S. Arab, M. Mojarrad, M. Motamedi, R. Mirzaei, M. H. Modarressi, J. Hadjati. Tumour Regression Induced by Co-administration of MIP-3α and CpG in an Experimental Model of Colon CarcinomaScandinavian Journal of Immunology 2013; 78(1): 28 doi: 10.1111/sji.12058
2
Yanal M Murad, Timothy M Clay, H Kim Lyerly, Michael A Morse. CPG-7909 (PF-3512676, ProMune®): toll-like receptor-9 agonist in cancer therapyExpert Opinion on Biological Therapy 2007; 7(8): 1257 doi: 10.1517/14712598.7.8.1257
3
Yanal M. Murad, Timothy M. Clay. CpG Oligodeoxyneucleotides as TLR9 AgonistsBioDrugs 2009; 23(6): 361 doi: 10.2165/11316930-000000000-00000
4
Arthur M. Krieg. Therapeutic potential of Toll-like receptor 9 activationNature Reviews Drug Discovery 2006; 5(6): 471 doi: 10.1038/nrd2059
5
Jörg Vollmer, Arthur M. Krieg. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonistsAdvanced Drug Delivery Reviews 2009; 61(3): 195 doi: 10.1016/j.addr.2008.12.008
6
Carole Bourquin, Susanne Schreiber, Sebastian Beck, Gunther Hartmann, Stefan Endres. Immunotherapy with dendritic cells and CpG oligonucleotides can be combined with chemotherapy without loss of efficacy in a mouse model of colon cancerInternational Journal of Cancer 2006; 118(11): 2790 doi: 10.1002/ijc.21681
7
Marion Jurk, Jörg Vollmer. Therapeutic Applications of Synthetic CpG Oligodeoxynucleotides as TLR9 Agonists for Immune ModulationBioDrugs 2007; 21(6): 387 doi: 10.2165/00063030-200721060-00006
8
Arthur M. Krieg. Development of TLR9 agonists for cancer therapyJournal of Clinical Investigation 2007; 117(5): 1184 doi: 10.1172/JCI31414
9
Srdjan Novaković, Vida Stegel, Andreja Kopitar, Alojz Ihan, Barbara Jezeršek Novaković. Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLsVaccine 2007; 25(49): 8241 doi: 10.1016/j.vaccine.2007.09.067
10
Christian Manegold, Donald Gravenor, Donald Woytowitz, Jörg Mezger, Vera Hirsh, Gary Albert, Mohammed Al-Adhami, David Readett, Arthur M. Krieg, Cynthia Gail Leichman. Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung CancerJournal of Clinical Oncology 2008; 26(24): 3979 doi: 10.1200/JCO.2007.12.5807
11
Udo Holtick, Max E Scheulen, Michael S von Bergwelt-Baildon, Martin R Weihrauch. Toll-like receptor 9 agonists as cancer therapeuticsExpert Opinion on Investigational Drugs 2011; 20(3): 361 doi: 10.1517/13543784.2011.553187
12
Su-Mi Bae, Yong-Wan Kim, Sun-Young Kwak, Yong-Wook Kim, Duck-Yeong Ro, Jong-Chul Shin, Choong-Hak Park, Sei-Jun Han, Chung-Hun Oh, Chong-Kook Kim, Woong-Shick Ahn. Photodynamic therapy-generated tumor cell lysates with CpG-oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cellsCancer Science 2007; 98(5): 747 doi: 10.1111/j.1349-7006.2007.00447.x
13
Misha D. Luyer, Wim A. Buurman, M??hamed Hadfoune, T Wolfs, Cornelis van??t Veer, Jan A. Jacobs, Cornelis H. Dejong, Jan Willem M. Greve. Exposure to Bacterial DNA Before Hemorrhagic Shock Strongly Aggravates Systemic Inflammation and Gut Barrier Loss via an IFN-??-Dependent RouteAnnals of Surgery 2007; 245(5): 795 doi: 10.1097/01.sla.0000251513.59983.3b
14
Arthur Krieg, Julie Himes. Nucleic Acids in Innate Immunity2008; : 129 doi: 10.1201/9781420068269.ch10
15
Kouji Maruyama, Zohair Selmani, Hidee Ishii, Ken Yamaguchi. Innate immunity and cancer therapyInternational Immunopharmacology 2011; 11(3): 350 doi: 10.1016/j.intimp.2010.09.012
16
Yukari Kuramoto, Shigeru Kawakami, Shuwen Zhou, Kyouichi Fukuda, Fumiyoshi Yamashita, Mitsuru Hashida. Efficient peritoneal dissemination treatment obtained by an immunostimulatory phosphorothioate-type CpG DNA/cationic liposome complex in miceJournal of Controlled Release 2008; 126(3): 274 doi: 10.1016/j.jconrel.2007.12.007
17
Jing Wang, Yuko Shirota, Defne Bayik, Hidekazu Shirota, Debra Tross, James L. Gulley, Lauren V. Wood, Jay A. Berzofsky, Dennis M. Klinman. Effect of TLR Agonists on the Differentiation and Function of Human Monocytic Myeloid-Derived Suppressor CellsThe Journal of Immunology 2015; 194(9): 4215 doi: 10.4049/jimmunol.1402004
18
Michael J. McCluskie, Risini D. Weeratna. Immunopotentiators in Modern Vaccines2006; : 73 doi: 10.1016/B978-012088403-2/50006-X
19
Amy Gillgrass, Ali Ashkar. Stimulating natural killer cells to protect against cancer: recent developmentsExpert Review of Clinical Immunology 2011; 7(3): 367 doi: 10.1586/eci.10.102
20
Risini D. Weeratna, Heather L. Davis, Liana Medynski, Arthur M. Krieg. Potential use of CpG ODN for cancer immunotherapyUpdate on Cancer Therapeutics 2006; 1(1): 49 doi: 10.1016/j.uct.2006.04.002